Botox for crow’s feet: why the trial measured a smile, not every resting crease

BOTOX Cosmetic is FDA-approved for temporary improvement of moderate-to-severe lateral canthal lines—often called crow’s feet—associated with orbicularis oculi muscle activity. In the pivotal studies, the key response was evaluated at maximum smile at Day 30. That result does not promise that every crease visible while the face is at rest will disappear. Ask the injector to document both expressions and the specific result you want before accepting a crow’s-feet package. ^{1 2}

The question here is not whether toxin or filler is “better.” The broader injectable comparison handles mechanism and product categories. This guide reads one label endpoint closely so a consumer can tell the difference between what was studied and what a photograph or sales phrase might imply.

The label’s measurement has a specific expression

The BOTOX Cosmetic label describes lateral canthal lines linked to orbicularis oculi activity. Its controlled studies assessed line severity at maximum smile, including a Day 30 composite investigator-and-subject responder measure. ¹ The original phase 3 research also centered its primary crow’s-feet outcome on maximum-smile severity. ² A result at maximum smile answers an expression-line question; it is not a direct measure of every etched mark in resting skin.

The two line views can coexist. A person may see a strong movement-driven fan when smiling and a fine resting crease afterward. Reducing selected muscle activity can change the first; improvement in the second may be variable and should not be guaranteed. Skin quality, sun exposure, age, prior treatment and anatomy may also shape expectations, but no online checklist can assign an individualized result.

Approval is for an exact product and use

The BOTOX Cosmetic label has its own indication, preparation, product-specific units, treatment sites, warnings and adverse-effect information. ¹ It does not make every botulinum-toxin brand, technique, dose or combination automatically equivalent. A quote that simply says “Botox crow’s feet” should specify the product that will actually be administered and whether the proposed plan follows its current label or involves an off-label component.

The label’s dose and injection map are prescriber information, not instructions for a consumer to demand a fixed amount. Muscle behavior, prior results and health history require individual assessment. “Baby Botox” and “preventive Botox” are marketing phrases, not separate FDA indications or guarantees of a natural look.

Do not use a resting crease to justify an automatic filler add-on

A resting line may lead a provider to discuss other approaches, but it does not make filler a routine approved crow’s-feet treatment. FDA filler approvals are product- and site-specific, and FDA describes rare but severe consequences of unintended intravascular injection, including vision loss and stroke. ³ An approval for another facial site would not automatically cover lateral canthal lines.

If a practice proposes a second procedure, request its exact product, site, indication, intended mechanism, risk plan and alternative. The goal is not to turn one cosmetic preference into a treatment stack. A thoughtful provider can also say that the resting line may persist and that no additional procedure is needed or suitable.

The eye-history question matters even in a wrinkle visit

The BOTOX Cosmetic label reports dry eye associated with injections in or near the orbicularis oculi. ¹ Tell the injector about existing dry eye, contact lenses, prior eye surgery, difficulty closing the eyes, unusual blinking, and any other relevant eye symptoms. Those facts do not automatically rule out treatment, but they belong in assessment and consent. The dry-eye-after-Botox guide covers what to do when symptoms arise; this visit is about documenting the baseline and planning follow-up.

Ask who to contact if new dryness, light sensitivity or vision changes occur, and who can arrange eye assessment if needed. A cosmetic result photograph cannot evaluate the tear surface. No promise about wrinkle softening should replace that practical handoff.

Use photographs as a consistent measurement, not a result guarantee

If a practice uses before-and-after images, ask for the same lighting, camera distance and facial expression at both visits. A maximum-smile baseline compared with an at-rest follow-up can make a change look larger than the label’s measured endpoint. Makeup, retouching and a different head angle can also obscure what was actually assessed. This is a documentation principle, not a way for a consumer to diagnose muscle behavior from a selfie.

The Day 30 trial endpoint is one planned assessment point. It is not a promised onset date, personal duration or guarantee of complete line removal. A follow-up should return to the initial target: how the lateral canthal lines look during the expression that mattered to the patient, what remains at rest, and whether eye comfort or function changed. If the desired outcome is different from what the label study measured, the provider should say so before treatment.

Set one testable expectation

Before booking, ask the injector to show and record your lines at maximum smile and at rest; identify which view the treatment targets; name the actual toxin product and label status; discuss eye history and meaningful risks; and state when the outcome will be reviewed. Treomark’s Botox provider page can help locate South Florida practices. The standard to compare is a product-specific, expression-specific consultation—not a promise that “all crow’s feet” will disappear.